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Abstract
Background: Doxorubicin (Dox) is widely used to treat progressed bladder cancer after transurethral resection.
The use of Dox-chemotherapy has been limited due to induced drug resistance and cumulative cardiotoxic effects.
N-benzyladriamycin-14-valerate (AD198), a novel derivative of Dox, has a potential to become a more effective
treatment than Dox by overcoming drug resistance and cardio-toxicity as shown in the rodent model of lymphoma
in vivo. The purpose of this study was to compare the efficacy of Dox and AD198 and explore their mechanisms in
inhibition on human bladder cancer cells in vitro.
Methods: We evaluated the effects of Dox and AD198 on cell viability of human transitional cell carcinoma (TCC)
cell lines T24 and UMUC3 by MTS assay in vitro. The effects of Dox and AD198 on cell apoptosis were determined
by caspase 3/7 assay, generation of reactive oxygen species (ROS), and Western Blotting (WB) analysis.
Results: AD198 was more effective than Dox in inhibition of cell viability of T24 and UMUC3 cells in vitro. Both Dox
and AD198 significantly increased the generation of ROS and induced apoptosis in caspase-dependent and
-independent manner in T24 and UMUC3 cells. AD 198 induced significantly higher production of ROS as
compared to Dox in human TCC cells. Dox and AD198 activated the pro-apoptotic p38 MAPK pathway; however,
on the other hand also increased phosphorylation of AKT, an anti-apoptotic signaling pathway, in T24 and UMUC3
cells. Combined treatment of PI3K inhibitor (LY294002) with Dox or AD198 inhibited cell viability of T24 and UMUC3
cells more effectively than any of drug treatments alone.
Conclusions: These data suggest that AD198 as novel derivative of Dox, could be a used as effective treatment for
bladder cancer. Dox and AD198 induced PI3K/AKT signaling pathway that is a one of the indicators of pro-survival
and possible drug-resistance mechanisms of chemotherapies in bladder cancer. Combined therapies of Dox or
AD198 with inhibitors of PI3K/AKT signaling pathway might lead to more effective treatment outcome for patients
diagnosed with bladder cancer based on our in vitro experiments.
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Background
Bladder cancer is the 6th most common cancer in the
United States, with high rates of recurrence [1, 2].
While the exact reasons are unknown, bladder cancer
presents itself four times more in males than females
[1, 3]. Urothelial cancer, also known as transitional cell
carcinoma (TCC), is the most common type of bladder
cancer in the western world and accounts for over 90 % of
all bladder cancer cases [2, 4]. The 5-year survival rates
for patients diagnosed with the earlier stages of the
bladder cancer are 69.2 %. However; the 5-year survival
rates for patients diagnosed with invasive bladder cancer
at stage IV are only 5.5 % [2]. The biggest challenges in
treatment of bladder cancer are the high rates of reoccur-
rence and progression from non-invasive to invasive
stages of bladder cancer. The invasion of bladder cancer
into the muscle layer of the bladder serves as major
prognostic marker for the development of the treatment
plan [3]. Tobacco products have been determined to be
the highest environmental risk factor for developing
bladder cancer [2]. Other environmental risk factors
for bladder cancer include occupational exposure and
chemotherapy drugs, while non-environmental risk
factors include age, gender, race, obesity and family
history [1, 2, 5].
Superficial bladder cancer is well managed by trans-
urethral resection (TUR), followed by an intravenous or
intravesical (directly into the bladder) administrations of
chemotherapeutic treatment, such as mitomycin,
epirubicin or doxorubicin (Dox) [6–8]. The intravesical
injection of bacillus Calmette-Guérin (BCG), as adjuvant
immunotherapy, activates immune system in the pa-
tient and greatly increases progression free survival
rates [8, 9]. The management treatment for patients
with muscle invasive bladder cancer is usually a rad-
ical cystectomy (removal of whole bladder) mostly
followed by adjuvant therapy, such as chemotherapy
and radiation therapy [3]. Chemotherapy protocols
without radiation include: cisplatin alone, or cisplatin
with 5-flourouracil or mitomycin with 5-flourouracil
[10]. Chemotherapy protocols in conjunction with
radiation include: gemcitabine with cisplatin, the
MVAC protocol - methotrexate, vinblastine, Dox
(Adriamycin), cisplatin or combination of carboplatin
with either paclitaxel or docetaxel [10].
Dox is an anthracycline antibiotics and is one of the
most widely used anti-cancer drugs [8, 11]. Dox interacts
with topoisomerase II (TOPOII) [12–14] and induces
apoptosis through production of reactive oxygen species
(ROS) and by inducing DNA damage in bladder cells [15].
Dox induces ROS production through p53-dependent and
p53-independent mechanisms [16, 17]. However, other
mechanisms of Dox action remain unclear. While Dox
has been successful in treating patients diagnosed with
different cancers, long term use of Dox has two major set-
backs. Firstly, Dox induces drug resistance through
the upregulation of the multi-drug resistance 1
(MDR1) gene, also known as p-glycoprotein in the
cell [18, 19]. Secondly, long term use of Dox has been
linked to acute cardiotoxicity [20].
N-benzyladriamycin-14-valerate (AD198), one of the
derivatives of Dox, which shows improvement in cardio-
toxicity as compared to Dox [21]. The addition of an N-
benzyl ring improves the lipophilic properties of AD198
and allowing rapid localization of AD198 in the
cytoplasm of cells [21]. The structural similarity of a
moiety of the AD198 molecule to diacylglycerol (DAG)
allows AD198 to interact with the regulatory subunit of
PKC-δ by releasing the catalytic subunit [22]. The re-
leased PKC-δ catalytic subunit attributes to its cytotoxic
effects by inducing mitochondrial membrane depolarization
and inducing ROS production [22]. In cardiomyocytes,
AD198 activates PKC-ε, which attributes to cardio-
protective effects by Dox-induced ROS production [23].
AD198 has been shown to be effective in inhibition of cell
growth of mouse lymphoma and multiple-myeloma models
[24]. In addition, AD198 is more effective in inhibition of
cell proliferation and inducing apoptosis in canine TCC
and osteosarcoma primary cell lines than Dox through the
p38 MAPK signaling pathway [25]. Cardio-toxicity, which
is a major concern for patients receiving Dox treatment,
has not been detected when rats were treated with AD198
[26]. In rats, low dose administration of AD198 after Dox-
induced cardiotoxicity, attenuated markers of cardiotoxi-
city, when compared to Dox alone [27]. This cardio-
protective property of AD198 has been attributed to ac-
tivation of PKC-ε, while PKC-ε knockout mice did not
benefit from cardio protective effects of AD198 [23].
AD198 has not been evaluated for its potential use in
bladder cancer treatment. So in this study, we evaluated
the efficacy and mechanisms of Dox and its derivative,
AD198 on cell proliferation and apoptosis in human
UMUC3 and T24 TCC cell lines in vitro.
Methods
Reagents and antibodies
Unless otherwise stated, all reagents and media were pur-
chased from Fisher Scientific (Pittsburgh, PA.) Dox and
LY294002 were purchased from Sigma-Aldrich, St. Louis,
MO. N-benzyladriamycin-14-valerate (AD198) was a kind
gift from Dr. Leonard Lothstein (The University of
Tennessee, Health Science Center in Memphis) [21]. The
following antibodies were purchased from Santa Cruz
Biotechnology, (Santa Cruz, CA): Actin-HRP, p-ERK1/2,
ERK1/2, AKT and p38. The following antibodies were pur-
chased from Cell Signaling (Boston, MA): PARP, p-AKT
(Serine 473 and Threonine 308), p-GSK3β and p-p38.
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Cell lines
Human transitional cell carcinoma T24 and UMUC3 cell
lines were purchased from ATCC (Manassas, VA). The
cells were grown in the following media: T24 in McCoy’s
media, UMUC3 in MEM media containing 10 % FBS
and penicillin/streptomycin mixture (Fisher Scientific,
Pittsburgh, PA) in 37 °C and 5 % CO2.
Proliferation assay
Cells were plated in 96-well plates at 5 × 103 cells per
well and allowed to attach for 24 h. After seeding, cells
were treated with AD198 or Dox in dose-dependent
manner in complete media for additional 48 h. DMSO
was used as control. For co-treatment with PI3K in-
hibitor (LY294002), the cells were pretreated with
20 μM LY294002 for 30 min prior to AD189 or Dox
treatments followed by combined treatment for 48 h.
After treatment, the viability of cells was measured
using CellTiter 96® Aqueous One Solution Cell Prolif-
eration Assay (Promega, Madison, WI) according to
manufacturer’s protocol. Briefly, 20 μL of the MTS
reagent was added to each well and allowed to incu-
bate at 37°C for 1 h. Absorbance was measured at
490 nM using a plate reader (Bio-Tek instruments,
Winooski, VT). The treatment results were normal-
ized to the DMSO controls.
Reactive Oxygen Species (ROS) assay by flow cytometry
After cells were treated with Dox or AD for 24 h, the cells
were incubated with 5 μM dihydrogen-dichlorodihydro-
fluorescein-diacetate (H2DCF-DA; Life Technologies,
Grand Island, NY) for 1 h. The cells were then washed
twice with PBS and trypsinized. The trypsin was neutral-
ized and the collected cells were centrifuged at 5000 rpm
for 5 min. The cell pellet was re-suspended in 1 mL of
PBS and the fluorescence was measured at 485 nM excita-
tion and 530 nM emission using flow cytometer (BD
Accuri® BD Sciences, San Jose, CA). The treatment results
were normalized to the DMSO controls.
Caspase-3/7 assay
Cells were plated in 6-well plates at 5 × 105 cells per
well. After 24 h, cells were treated with AD198 or Dox
for additional 24 h. After treatment, cells were washed
twice with PBS, and cell lysates were harvested using
RIPA buffer. Protein concentration was measured using
Bradford BCA assay. Forty micrograms of proteins
were used for detection of caspases 3/7 following the
Caspase Glo® 3/7 Substrate protocol (Promega). After
1 h incubation with reagents, the luminescence was
measured using FLx800 plate reader (Bio-Tek instruments,
Winooski, VT). The treatment data were normalized to the
DMSO controls.
Western blot
Cells were plated at 1.5 × 106 cells per 10-cm plate.
Twenty four hours after plating, the cells were treated
with AD or Dox for 24 h in dose-depend manner (0.1,
0.5 and 1.0 μM). For co-treatment with PI3K inhibitor
(LY294002), the cells were pretreated with 20 μM
LY294002 for 30 min prior to AD or Dox co-treatments
for additional 24 h. After treatment, the cells were
washed twice with PBS and lysed using cold RIPA buffer
containing protease/phosphatase inhibitors. The cell ly-
sates were kept at −80 °C until further analysis. Protein
concentrations were measured using the BCA protein
assay. Equal amount of proteins (60 μg) were loaded
onto SDS-PAGE gels and transferred to a nitrocellulose
membrane. After blocking, the membranes were incu-
bated with primary antibodies at 4 °C overnight and then
incubated with horseradish peroxidase-conjugated sec-
ondary antibodies for 1 h at room temperature. The im-
munoreactive bands were visualized using enhanced
chemiluminescence system (Fisher) and acquired using
the ImageQuant LAS4000 (GE Life Sciences, Pittsburgh,
PA.) The densitometry analysis of proteins were normal-
ized to actin from three independent WB experiments
using ImageJ (NIH) software.
Statistical analysis
Statistical analysis were conducted using paired Student
t-test to established significance. Results were considered
statistically significant at *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001
when treatments were compared to control groups and
#p ≤ 0.05, ##p ≤ 0.01, ###p ≤ 0.001 when Dox groups were
compared to AD198 groups at the same doses, or when
Dox or AD198 groups were compared to LY + Dox or
LY + AD198 groups.
Results
DOX and AD198 inhibited cell viability of human TCC cells
Human TCC cell lines, T24 and UMUC3 were treated
with 0.1, 0.5, 1 and 5 μM of Dox and AD198 for 48 h, as
shown in Fig. 1. Both, Dox and AD198, significantly re-
duced the proliferation of T24 (Fig. 1a) and UMUC3
(Fig. 1b) cells in dose-dependent manner. AD198 was
significantly more effective in inhibition of cell viability
in both T24 and UMUC3 cells as compared to Dox at
the concentrations of 0.1 and 5 μM.
Dox and AD198 induced ROS production in human TCC cells
The effects of Dox and AD198 on generation of cellular
ROS was evaluated using H2DCF-DA assay. Dox and
AD198 both significantly increased ROS in T24 (Fig. 2a)
and UMUC3 (Fig. 2b) cells after 24 h treatment; and in
addition, AD198 showed significantly higher activation
of ROS production as compared to DOX with 3-fold vs
2-fold increase in T24 cells and 6-fold vs 3-fold increase
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in UMUC3; respectively (*p ≤ 0.05 in T24 and **p ≤ 0.01
in UMUC3) as shown in Fig. 2.
Dox and AD198 induced apoptosis in human TCC cells
through activation of caspase cascade
The effects of Dox and AD198 on cell apoptosis were
evaluated using the caspase-3/7 activities assay. Dox and
AD198 both increased apoptosis in T24 and UMUC3
cells; however, Dox showed significantly higher caspase
activation than AD198 in both TCC cell lines (##p ≤ 0.01
in T24 and ###p ≤ 0.001 in UMUC3) as shown in Fig. 3a.
Poly (ADP-ribose) polymerase (PARP) is a family of
proteins involved in genomic stability and are down-
stream targets, which are cleaved by caspases to produce
89 and 24 kD fragments [28, 29]. The presence of
degraded PARP is generally considered as a marker of
apoptosis [28]. Dox and AD198 (1 μM) treatments in-
creased a cleavage of PARP in both tested cells as con-
firmed by WB analysis (Fig. 3b). Densitometry values of
cleaved PARP protein after Dox and AD198 treatments
were normalized to actin and then to control group as
shown in Fig. 3c. A statistically significant increases in
Fig. 1 DOX and AD198 inhibited cell viability of human TCC cells. (a) Human urinary bladder transitional cell carcinoma (TCC) cells T24 and
(b) UMUC3 cells were treated with Dox (black bars) and AD198 (white bars) at 0.1, 0.5, 1 and 5 μM for 48 h and compared to control groups. Cell
proliferation was determined by MTS assay and relative cell growth rate was normalized to control counterpart. Values represent mean ± S.E. of
four replicates from three independent experiments. Paired Student t-tests were used to compare Dox and AD198 treatment to control; * p≤ 0.05
and *** p≤ 0.001. Paired Student t-tests were used to compare among Dox and AD198 group at the same dose treatment; ##p≤ 0.01 and ###p≤ 0.001
Fig. 2 Dox and AD198 induced ROS in human TCC cells. (a) T24 and (b) UMUC3 cells were treated with 1μM Dox and AD198 for 24 h and ROS
levels were measured with dihydrogen-dichlorodihydro-fluoresceindiacetate assay; percent of ROS positive cells were measured and normalized
to the control. Values represent mean ± S.E. of three independent experiments. Paired Student t- tests were used to compare Doxand AD198
treatments to controls, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. Paired Student t-tests were used to compare among Dox and AD198 group at the
same dose treatment; #p ≤ 0.05 and ##p ≤ 0.01
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PARP cleavage (***p ≤ 0.001 and **p ≤ 0.01) by 17- and 11-
fold were observed with Dox treatment as compared to
control treatments in T24 and UMUC3 cells; respectively
(Fig. 3c). Also Dox significantly increased PARP cleavage
by 3- and 4-fold (#p ≤ 0.05) as compared to AD198 treat-
ment in T24 and UMUC3 cells; respectively (Fig. 3c).
Dox and AD198 activated PI3K/AKT signaling pathway in
human TCC cells
To better understand the mechanisms of AD198 and
Dox-induced cell growth inhibition in T24 and UMUC3
cells, we investigated role of PI3K/AKT and MAPK sig-
naling pathways. Dox increased the phosphorylation of
AKT protein at both Ser473 and Thr308 sites in T24
and UMUC3 cells in time- and dose-dependent manner
(Fig. 4). GSK-3β is a critical downstream element of the
PI3K/AKT cell survival pathway, and when phosphory-
lated, its pro-apoptotic function is attenuated by AKT
[30]. Dox increased phosphorylation of GSK-3β in dose-
dependent manner as shown in Fig. 4a. There was no
significant increase in the phosphorylation of ERK1/2 in
either TCC cells when treated with Dox or AD198
(Fig. 4a). The p38 MAPK has been shown to be activated
by ROS and plays a vital role in apoptosis [31, 32]. Both
Dox and AD198 increased phosphorylation of p38
MAPK in a time-dependent manner with increased
Fig. 3 Dox and AD198 induced apoptosis in human TCC cells. a T24 and UMUC3 cells were treated with 1 μM Dox and AD198 for 24 h and
caspase-3/7 activities were measured using the Caspase-Glo 3/7 luminescence assay. Relative caspase-3/7 activities were normalized to control.
Values represent mean ± SE of three independent experiments. Paired Student t-test were used to compare treatment to control **p≤ 0.01,
***p ≤ 0.001. Student t-tests were used to compare among Dox and AD198 treatments ## p≤ 0.01, ### p≤ 0.001. b T24 and UMUC3 cells were
treated with 1 μM Dox and AD198 for 24 h. The expression of PARP (cleaved fragment) was evaluated by WB analysis. Actin was used as a loading
control. c Densitometry evaluation of cleaved PARP protein bands from WB analysis was done using ImageJ software. Values represent mean ± S.E. of
measured densitometry of each band from three independent experiments. Paired Student t-tests were used to compare controls to Dox and AD198
treatments, *p≤ 0.05, **p≤ 0.01, and ***p≤ 0.001. Paired Student t- tests were used to compare Dox to AD198 treatment, #p≤ 0.05
Smolensky et al. BMC Cancer  (2015) 15:927 Page 5 of 11
activation at 1–3 h after AD198 and Dox treatments in
T24 cells (Fig. 4b). In UMUC3 cells, the activation of
p38 was seen to be higher with AD198 than with Dox
treatments, confirming previous results of higher ROS
production by AD198 (Fig. 4b).
Inhibition of PI3K/AKT signaling pathway sensitizing the
cytotoxic effects of Dox and AD198 in human TCC cells
Dox and AD198 activated AKT pro-survival signaling
pathway that is an indicator of resistance of cells to
chemotherapy. To confirm our hypothesis, we tested the
effects of PI3K inhibitor, LY294002, in combination with
Dox or AD198 on cell growth of TCC cells. Co-
treatment with LY294002 increased the anti-proliferative
effects of both Dox and AD198 in T24 and UMUC3
cells (Fig. 5a). In order to further investigate the PI3K/
AKT inhibitor’s chemosensitizing effects to Dox and
AD198 chemotherapies, we measured caspase-3/7 activ-
ities and PARP cleavage. Indeed, co-treatment of Dox
and AD198 with PI3K inhibitor, LY294002, increased
caspase-3/7 activation and PARP cleavage in both T24
and UMUC3 cells as shown in Fig. 5b and c. LY294002
inhibited the AD198- and Dox-induced phosphorylation
of AKT at Thr308 and Ser473 sites as shown in Fig. 5d.
In addition, higher levels of active (unphosphorylated)
GSK3β were present when T24 and UMUC3 cells were
co-treated with Dox or AD198 and LY294002.
Discussion
Dox has been used to treat human bladder cancer for
over three decades and continues to be one of the most
common chemotherapeutic agent [33]. Dox is not as
Fig. 4 Dox activated AKT signaling pathway in human TCC cells in dose- and time-dependent manner. a T24 and UMUC3 cells were treated with
0.1, 0.5 and 1 μM Dox and AD198 for 24 h. Protein levels of p-AKT (T308), p-AKT (S473), AKT, p-GSK-3β, p-ERK1/2 and ERK1/2 were detected by
WB. Actin was used as a loading control. b T24 and UMUC3 cells were treated with 1 μM Dox and AD198 for 0, 0.5, 1, 3, 6 and 24 h. Protein levels
of p-AKT (T308), p-AKT (S473), AKT, p-p38, p38, p-ERK1/2 and ERK1/2 were detected by WB. Actin was used as a loading control
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Fig. 5 (See legend on next page.)
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effective alone as it is in combination with other drugs;
however, Dox increases side effects and decreases com-
pletion of regimen due to intolerances by the patients
[34]. Another setback of Dox in the treatment of bladder
cancer is the development of drug resistance by up-
regulation of p-glycoprotein efflux transporter protein
expressions. The established Dox-resistant bladder can-
cer cell lines, KK47/ADM, shows that complete reversal
of resistance was not possible even when Dox was used
in combination with a sensitizing agent, verapamil [35].
The development of novel derivatives of Dox may over-
come those Dox adverse events, and even exceed its
anti-cancer effects [36].
A novel derivative of Dox, AD198 has been developed
by Dr. Lothstein’s group [21]. AD198 is a highly
lipophilic drug, which rapidly localizes to the cellular
cytoplasm and it has been shown to circumvent efflux
transport by p-glycoprotein in Dox-resistant macrophage
cells [21, 37]. AD198 has been shown to overcome Bcr-
Abl pro-survival signaling pathway in human leukemia
cells through the activation of ERK1/2 and STAT-5
followed by cytochrome C release and apoptosis [38].
Breast and ovarian cancer cell lines, which are resistant
to Dox due to p-glycoprotein expression, have been
shown to rapidly accumulate AD198 in the cytoplasm.
The efficacy of AD198 to inhibit cell growth is compar-
able to Dox treatment in non-resistant cells [39]. Our re-
sults are in agreement with this study and confirmed that
AD198 anti-proliferative effect was similar and compared
to Dox in T24 and UMUC3 cells. This might be relevant
for the intravesicular treatment of bladder cancer, where a
high dose of the Dox is used (~200 mM) [8].
It has been shown that AD198 and Dox have a similar
effect in generating ROS in murine cardiomyocytes [23].
However; ROS production was induced by AD198 more
than by Dox in both tested human bladder cell lines
(Fig. 2). In addition to ROS production in the cytoplasm,
Dox induces DNA damage via Topoisomerase II, while
AD198 mainly functions in the cytoplasm by increasing
ROS and activating PKC-δ [40]. In mouse myeloid cells,
AD198 induces apoptosis through activation of PKC-δ
and is not effected by the expression of Bcl-2 [22].
AD198 acts through PKC-δ-independent manner in
TRAF-3 deficient mouse B-lymphoma cells through the
suppression of oncogenic protein c-Myc [24]. AD198
might be beneficial for treatment of c-Myc overexpress-
ing cancer cells. While AD198 had an equal or greater
anti-proliferative and ROS generating effects than Dox in
TCC, it showed significantly less caspase activation and
PARP cleavage in both T24 and UMUC3 (Fig. 3a–c). It
has been previously shown that AD198 induces
cytochrome-C release and initiate mitochondrial-activated
apoptosis, even when caspase activation is blocked by a
pan-caspase inhibitor, Z-VAD-FMK [22]. In contrast, Dox
has been shown to function in a caspase-dependent man-
ner in T-leukemia cells and apoptosis was inhibited when
Jurkat cells were treated with Z-VAD-FMK [41]. Dox has
been shown to induce apoptosis in ROS-independent
manner in cardiomyocytes [42]. Our data provides
evidence that AD198 induced apoptosis in caspase-
dependent and -independent pathways. Dox, on the other
hand, induce apoptosis primarily through caspase-
dependent pathway.
To further investigate the differences in mechanisms
between Dox and AD198 action in TCC cells, we inves-
tigated PI3K/AKT and MAPK signaling pathways. AKT
has been shown to increase drug resistance in other
cancers and PI3K itself can contribute to expression of
multidrug resistance protein 1 (MDR1) to induce drug
resistance [30, 43, 44]. Dox activates the PI3K/AKT
pathway in several cancers including ovarian, hepatic
and breast cancer cells [45–47]. Activation of AKT by
(See figure on previous page.)
Fig. 5 Inhibition of AKT1 signaling pathway sensitizing the cytotoxic effects of Dox and AD198 in human TCC cells. a T24 and UMUC3 cells were treated
with Dox and AD198 (1 μM) with and without LY294002 (LY, 20 μM) for 48 h and compared to control groups. Cell proliferation was determined by MTS
assay and relative cell growth rate was normalized to control counterpart. Values represent mean ± SE of four replicates from three independent
experiments. Paired Student t-tests were used to compare DOX and AD198 treatments to control; ***p≤ 0.001. Paired Student t-tests were used to
compare Dox to Dox + Ly and AD198 to AD198 + LY treatment, ###p≤ 0.001. b T24 and UMUC3 cells were treated with DOX and AD198 (1 μM) with
and without LY294002 (20 μM) for 24 h and caspase activities were measured using the Caspase-Glo 3/7 luminescence assay. Relative caspase activities
were normalized to control. Values represent mean ± SE of three independent experiments. Paired Student t-tests were used to compare treatment to
control **p≤ 0.01, ***p≤ 0.001. Paired Student t-tests were used to compare Dox to Dox + Ly and AD198 to AD198 + LY treatments, ###p≤ 0.001. c T24
and UMUC3 cells were treated with Dox and AD198 (1 μM) with and without LY294002 (20 μM) for 24 h. The expression of PARP (cleaved fragment)
were evaluated by WB analysis. Actin was used as a loading control. Densitometry evaluation of PARP protein bands from WB analysis was done using
ImageJ software. Values represent mean ± S.E. of measured densitometry of each protein’s band from three independent experiments. Paired Student
t-tests were used to compare controls to Dox and AD198 treatments, *p≤ 0.05, **p≤ 0.01, and ***p≤ 0.001. Paired Student t-tests were used to compare
Dox to AD198 treatment, #p≤ 0.05, ##p≤ 0.05, and ###p≤ 0.001 d T24 and UMUC3 cells were treated with Dox and AD198 (1 μM) with and without
LY294002 (20 μM) for 24 h. The expression of p-AKT (T308), p-AKT (S473), AKT1 and p-GSK-3β proteins were evaluated by WB analysis. Actin was used as
a loading control. Densitometry evaluation of p-AKT (T308), p-AKT (S473) protein bands from WB analysis was done using ImageJ software.
Values represent mean ± S.E. of measured densitometry of each band from three independent experiments. Paired Student t-tests were used
to compare controls to Dox and AD198 treatments, *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001. Paired Student t-tests were used to compare Dox
to Dox + LY or AD198 to AD198 + LY treatments, #p ≤ 0.05, ##p ≤ 0.01
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Dox has been linked to the presence of human epider-
mal growth factor receptor 3 (HER3, ERBB3 ) in ovarian
cancer and was attenuated by the addition of tyrosine
kinase inhibitors lapatinib and/or erlotinib [45]. In our
study, Dox more efficiently phosphorylated AKT
(Ser473 and Thr308) and its downstream target GSK3β
than AD198 in dose- and time- dependent manner
(Fig. 4a and b). PI3K/AKT pathway has been greatly im-
plicated in the progression and prognosis in bladder
cancer patients [48]. The growth factor receptors in-
cluding ERBB2, ERBB3 and EGFR have been found to
be altered or amplified in bladder cancer and have the
potential to activate PI3K/AKT signaling pathway [49].
PI3K mutation is inversely associated with later stages,
indicating that mutation of PI3K is not crucial to blad-
der cancer progression [50, 51]. AKT after activation by
PIP3, has a wide range of downstream targets including
activation of anti-apoptotic targets such MDM2 and
mTOR as well as deactivation of apoptotic targets such
as BAD, GSK3β and TSC1 [52, 53]. It has been shown
that inhibition of PI3K sensitizes TCC cells to Dox
chemotherapy and lowers the IC50 of Dox when used in
combination with LY294002 [54]. We confirmed that co-
treatment of PI3K/AKT inhibitor with Dox or AD198 re-
duced cell proliferation more efficiently than Dox or
AD198 treatments alone in tested human bladder cells
(Fig. 5a). Furthermore, co-treatment of LY294002 with ei-
ther Dox or AD198 induced an activation of caspase-3/7
activity and cleavage of PARP than AD198 or Dox treat-
ments alone (Fig. 5b and c). In T24 and UMUC3 cells,
phosphorylation of GSK3β was decreased by co-
treatments, indicating that its pro-apoptotic function
was restored (Fig. 5d), while either Dox or AD198
alone increase phosphorylation of GSK3β indicating an
anti-apoptotic resistance activated by AKT signaling.
The tumor suppressor PTEN (phosphatase and tensin
homolog deleted on chromosome 10) antagonizes the
PI3K/AKT signaling pathway and mutation or decrease
of PTEN expression has been shown to be as a poor
prognostic marker in breast cancer patients [55]. The
Pten gene therapy in mice increases tumor sensitivity
to Dox therapy in vivo [56]. T24 cells have mutation in
PTEN gene, but cells express PTEN protein, while in-
tragenic deletion of PTEN gene in exons1-8 in UMUC3
cells results in no PTEN protein expression [57]. We
have observed that phosphorylation of AKT1 levels
were much higher in UMUC3 cells than T24 probably
due to absence of PTEN (data not shown).
Conclusions
In conclusion, we have shown that AD198 has compar-
able anti-proliferative efficacy as Dox in tested human
TCC cell lines in vitro. AD198 was more effective in
induction of ROS production. AD198 induced apoptosis
in caspase-dependent and -independent pathways. Dox,
on the other hand, induced apoptosis primarily through
caspase-dependent pathway. Both drugs activated PI3K/
AKT signaling pathway, which may explain a common
mechanisms of bladder cancer to acquire a drug resist-
ance. The inhibition of the PI3K/AKT pathway plays an
important role in increasing the effectiveness of Dox and
AD198 treatments in human bladder cancer cells in
vitro. AD198 a novel derivative of Dox, with no cardio-
toxic effects as has been shown in mice in vivo model,
may be a new candidate for the replacement of Dox
treatment in bladder cancer. Further investigations using
rodent animal model of bladder cancer in vivo are re-
quired to support these in vitro findings.
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